Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 7,579 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Clear all
Completed Phase 2 Interventional Results available

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
Withdrawal of immunosuppression and donor lymphocyte infusion
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 25 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
San Francisco, California • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • South Pasadena, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

NCT02758132
View directory record Official record
Conditions
Prostate Cancer
Interventions
Denosumab, Enzalutamide, Abiraterone, Prednisone
Biological · Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 4 Interventional

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

NCT03176849
View directory record Official record
Conditions
Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions
Vitamin D3, Standard Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

NCT00036738
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Disease
Interventions
Cyclosporine, Dasatinib, Fludarabine Phosphate, Imatinib Mesylate, Mycophenolate Mofetil, Nilotinib, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, Total-Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

NCT00006225
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin, recombinant interleukin-3, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational

Familial Myeloproliferative Disorders

NCT00666289
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia, Idiopathic Myelofibrosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational

Protocol For Collecting Long-Term Follow-Up Data On Recipients of Bone Marrow and Blood Stem Cell Transplant

NCT00674882
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Data Collection
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00089323
View directory record Official record
Conditions
Breast Cancer
Interventions
Bone Marrow Aspiration
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
49
States / cities
Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

NCT00994214
View directory record Official record
Conditions
Acromegaly
Interventions
BIM 23A760
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

NCT02497404
View directory record Official record
Conditions
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Interventions
5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab, Total Body Irradiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00039416
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

NCT03246906
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Mycophenolate Mofetil, Sirolimus
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).

NCT01988584
View directory record Official record
Conditions
Cerebral Palsy
Interventions
umbilical cord blood (hUCB) cells, Saline Infusion (Placebo), bone marrow derived mononuclear cells (BMMNCs)
Biological · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated Phase 4 Interventional Results available

Anderson Circulating Tumor Cell Burden (CTCB) Study

NCT00819832
View directory record Official record
Conditions
Cancer, Spinal Disease, Vertebral Compression Fractures
Interventions
Kyphoplasty, Vertebroplasty, Cavity SpineWand
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational

Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database

NCT06148493
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 20, 2026, 2:20 PM EDT
Withdrawn Phase 3 Interventional

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

NCT01361087
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Blood draw
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 20, 2026, 2:20 PM EDT
Not listed Phase 1Phase 2 Interventional

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

NCT00179816
View directory record Official record
Conditions
Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma, Hodgkin's Disease, Germ Cell Tumor
Interventions
High-Dose Chemotherapy with Tandem PBSC Rescue.
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of a Ghrelin Receptor Agonist on Muscle and Bone

NCT04021706
View directory record Official record
Conditions
Sarcopenia, Osteopenia
Interventions
Anamorelin Hydrochloride, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational

Comparison of Two Radial Head Implants

NCT01269840
View directory record Official record
Conditions
Radial Head Fractures
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Suprapatellar Versus Infrapatellar Nailing in Tibial Fractures: A Pilot Study

NCT01341418
View directory record Official record
Conditions
Tibial Fractures
Interventions
Suprapatellar approach, Infrapatellar approach
Procedure
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00471497
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic
Interventions
nilotinib, imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Vallejo, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated No phase listed Observational

Shilla Growth Permitting Spinal Instrumentation System for Treatment of Scoliosis in the Immature Spine

NCT00577226
View directory record Official record
Conditions
Scoliosis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Year to 10 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 20, 2026, 2:20 PM EDT